The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
The entity will undertake the installation, operation, and maintenance of sewage treatment plants
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
This predictive technology empowers people with diabetes to take preventive action before complications arise
Subscribe To Our Newsletter & Stay Updated
